BRISTOL-MYERS SQUIBB CO

BMS pauses autoimmune CAR‑T trials amid industry safety review, balancing innovation with risk, and setting the stage for stronger regulatory and payer confidence.

How Bristol‑Myers Squibb’s pipeline, strategic partnerships and regulatory focus shape its growth—insights on oncology, immune‑mediated diseases and smarter acquisitions.

Explore how a potential merger between AstraZeneca and Bristol‑Myers Squibb could reshape oncology, R&D and global market reach, boosting investor value and industry dynamics.

Investors eye Bristol‑Myers Squibb as a low‑beta, steady‑growth pharma stock—balanced legacy revenue, hefty R&D, and a growing oncology pipeline amid tech‑driven market swings.

Explore BMS’s market steadiness and cutting‑edge oncology pipeline—from Opdivo’s checkpoint success to radioligand and ADC breakthroughs that promise future growth.

Bristol‑Myers Squibb strengthens governance with a new non‑executive director and chair, boosting strategic oversight, compliance and investor confidence in its drug‑development focus.

Discover how Bristol‑Myers Squibb’s pivot from oncology to chronic disease cell therapy can unlock new revenue, expand patient reach, and secure a robust IP moat.

Discover how Bristol‑Myers Squibb’s deucravacitinib, a selective TYK2 inhibitor, offers a steroid‑sparing, oral solution for SLE with proven Phase III renal benefits.

Discover how Bristol‑Myers Squibb’s Kentucky LEADS program boosts early lung‑cancer detection using data‑driven tools—and the future of CAR‑T cell therapies.

Explore how Bristol‑Myers Squibb’s S&P 500 rank slip and new congressional probe could affect its valuation, pipeline, and market strategy.